Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy 2019
2019 Human neutrophil peptide-1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols 2019
2019 Significantly prolonged PT and APTT could indicate a wide spectrum of clinical manifestations in three patients with plasma cell disorders 2019
2019 Relative Deficiency of Plasma A Disintegrin and Metalloprotease with Thrombospondin Type 1 Repeats 13 Activity and Elevation of Human Neutrophil Peptides in Patients with Traumatic Brain Injury 2019
2019 Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura 2019
2018 Low Plasma ADAMTS13 Activity Is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Paediatric Trauma 2018
2018 Transfusion of platelets loaded with recombinant ADAMTS13 (A disintegrin and metalloprotease with thrombospondin type 1 repeats-13) is efficacious for inhibiting arterial thrombosis associated with thrombotic thrombocytopenic purpura 2018
2017 Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity: comment 2017
2017 Increased Plasma Levels of Human Neutrophil Peptides and Complement Activation Markers in Patients With Acquired Thrombotic Thrombocytopenic Purpura. 2017
2017 Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage 2017
2016 Acquired autoimmune thrombotic thrombocytopenic purpura in a case of severe haemophilia A 2016
2016 Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura 2016
2015 ADAMTS13 and von Willebrand factor interactions 2015
2014 Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery 2014
2012 Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease 2012
2010 Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress 2010
2010 Mutation of the protein kinase A phosphorylation site influences the anti-proliferative activity of mitofusin 2 2010
2009 Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site 2009
2009 Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy 2009
2009 Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes 2009
2008 Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells 2008
2008 Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13 2008
2006 Adenovirus-mediated Mfn2 gene induces the apoptosis of vascular smooth muscle cells after ballon injury of rat carotid artery 2006
2005 Monitoring CML28 mRNA levels in patients before and after HSCT by real-time quantitative RT-PCR 2005
2004 Liposome-mediated functional expression of multiple drug resistance gene in human bone marrow CD34+ cells 2004
2004 Role of extracelluar regulated protein kinases in FTY720-induced apoptosis of leukemia cell lines HL-60 and U937 2004
2004 Inhibition of NF-kappaB by mutant IkappaBalpha enhances TNF-alpha-induced apoptosis in HL-60 cells by controlling bcl-xL expression. 2004
2004 Inhibition of NF-κB by mutant IκBα enhances TNF-α -induced apoptosis in HL-60 cells by controlling bcl-XL expression 2004
2002 Regulative function of telomerase and extracelluar regulated protein kinases to leukemic cell apoptosis 2002
2002 Regulative function of extracelluar regulated protein kinases and telomerase in apoptosis of hepatocarcinomatous cell SMMC-7721 2002
2001 [Antisense Oligodeoxynucleotide Directed to NF-kappaB-RelA Down-Regulates bcl-x(L) mRNA in Drug-Resistant Leukemia Cell Line HL-60/E6] 2001
2001 Effect of antisense oligodeoxynucleotide directed to NF-κB-RelA on bcl-x L mRNA in extended drug resistance leukemia cell line HL-60/E6 2001

Full Name

  • Wenjing Cao